Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JOHNSON & JOHNSONJNJ · Entity 2722 | Director | April 23, 2026 | April 27, 2026 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | August 13, 2026 | August 17, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 05, 2020 | May 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JOHNSON & JOHNSON
Report date April 23, 2026 · Filed April 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 5,359.3973 |
Reported balance
After 2026-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-23 · Grant · Acquired 975 · Balance 5,359.3973 F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).
F2: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person.
Maze Therapeutics, Inc.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.67 · Expires 2036-08-12 | Direct | 36,000 |
Reported balance
After 2026-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-13 · Grant · Acquired 36,000 · Balance 36,000 F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on September 13, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
WEST PHARMACEUTICAL SERVICES INC
Report date May 05, 2020 · Filed May 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,753.6715 |
Reported balance
After 2020-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-05 · Grant · Acquired 975 · Balance 48,753.6715 F1: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
F2: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 1,659 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
Mirror Merger Sub 2, LLC
Report date March 01, 2021 · Filed March 03, 2021
Section 16 reporting ended · disclosed 2021-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-01 · Disposition to issuer · Disposed 5,840 · Balance 0 F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock. F2: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Stock Unit is the economic equivalent of one share of non-voting common stock.
F2: This Deferred Stock Unit award was canceled and converted in the March 1, 2021 merger of the Issuer and Morgan Stanley (the Merger) into the right to receive a cash payment of $73 per share for a total of $426,320.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2016 Filed Nov 1, 2016 12:48 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 2,466 | $75.87 | $187,095.42 |
DisclosureSEC source: 0001225208-16-040900 · doc4.xml · nonDerivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,037.9422 F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.